EGFR and neoplasm: Moreover, the presence of pre-treatment EGFR T790M mutation in the baseline tissue was not significantly associated with the presence of pre-treatment EGFR T790M mutation in the baseline plasma or the emergence of acquired EGFR T790M mutation in plasma or rebiopsy tumor tissues at disease progression (Table 6).